Lovisa Afzelius

Investment Stage

Focus Areas

About Investor

Lovisa Afzelius is a General Partner at Flagship Pioneering, leading one of the firm's Business Units and its European branch, focusing on Pharmaceuticals, BioTech, and Digital Health at seed and Series A, with checks between $500K and $15M. A computational scientist by training with two decades of leadership experience, she joined Flagship in early 2020 as an Origination Partner, promoted to General Partner in September 2023. She has been founding CEO of Alltrna, founding CEO and board chair of Apriori Bio (a WEF 2023 Technology Pioneer), co-founder and CEO of Metaphore Biotechnologies, co-founder and CEO of Prologue Medicines, and a co-founder of Generate:Biomedicines (which recently IPO'd on Nasdaq) and Elsa. She has held leadership positions as CEO, co-founder, president, board chairman, and executive director in the EU biotech and pharma world, and was recognized on Inc. Magazine's Female Founders 250 list (2024) and the PharmaVoice 100 (2023). She holds degrees from the University of Gothenburg, Uppsala University, and an MBA from MIT Sloan.